The growing epidemic of fatty liver disease may have found unexpected therapeutic allies in cannabis-derived compounds that work through entirely novel mechanisms. Rather than targeting traditional pathways like inflammation or fat burning, these non-psychoactive cannabinoids appear to restore fundamental cellular energy systems that become disrupted in metabolic liver disease.
Controlled studies using obese mice revealed that both cannabidiol (CBD) and cannabigerol (CBG) significantly reduced liver fat accumulation and improved blood sugar control through enhanced phosphocreatine buffering systems. The compounds increased hepatic creatine kinase activity by restoring cellular energy reserves without altering fat oxidation rates. Comprehensive lipidomics analysis showed reduced harmful ceramides and triglycerides alongside increased beneficial phospholipids, particularly lysobisphosphatidic acids that correlated with restored lysosomal function.
This research illuminates a previously unknown therapeutic mechanism that distinguishes these cannabinoids from conventional metabolic interventions. While most treatments for fatty liver disease target fat synthesis or breakdown, CBD and CBG appear to work at the cellular powerhouse level by optimizing energy storage and utilization systems. The restoration of lysosomal activity suggests these compounds may address the cellular cleanup mechanisms that become impaired in metabolic dysfunction-associated steatotic liver disease. However, the mouse model limitations and four-week treatment duration leave questions about long-term efficacy and human translation. The findings represent preliminary but mechanistically intriguing evidence that could inform future therapeutic development for the 25% of adults worldwide affected by fatty liver disease, though clinical trials remain essential before therapeutic recommendations.